

# Veronica Balatti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11423674/publications.pdf>

Version: 2024-02-01

33  
papers

2,141  
citations

304368

22  
h-index

414034

32  
g-index

34  
all docs

34  
docs citations

34  
times ranked

3552  
citing authors

#	ARTICLE	IF	CITATIONS
1	tsRNA signatures in cancer. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 8071-8076.	3.3	202
2	NOTCH1 mutations in CLL associated with trisomy 12. Blood, 2012, 119, 329-331.	0.6	190
3	Dysregulation of a family of short noncoding RNAs, tsRNAs, in human cancer. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 5071-5076.	3.3	183
4	Karyotype-specific microRNA signature in chronic lymphocytic leukemia. Blood, 2009, 114, 3872-3879.	0.6	179
5	BCL2 and miR-15/16: from gene discovery to treatment. Cell Death and Differentiation, 2018, 25, 21-26.	5.0	146
6	In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation. Journal of Experimental Medicine, 2013, 210, 951-968.	4.2	121
7	miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia. Blood, 2011, 118, 3072-3079.	0.6	115
8	Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 8573-8578.	3.3	105
9	miR-15b/16-2 deletion promotes B-cell malignancies. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 11636-11641.	3.3	98
10	MicroRNAs Dysregulation in Human Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2011, 6, 844-851.	0.5	77
11	Role of microRNA in chronic lymphocytic leukemia onset and progression. Journal of Hematology and Oncology, 2015, 8, 12.	6.9	72
12	B-cell malignancies in microRNA $\frac{1}{4}$ -miR-17 $\frac{1}{4}$ -miR-17 $\frac{1}{4}$ -92 transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 18208-18213.	3.3	69
13	<i>TCL1</i> targeting <i>miR-3676</i> is codeleted with tumor protein p53 in chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 2169-2174.	3.3	63
14	Role of the tRNA-Derived Small RNAs in Cancer: New Potential Biomarkers and Target for Therapy. Advances in Cancer Research, 2017, 135, 173-187.	1.9	60
15	Tcl1 protein functions as an inhibitor of de novo DNA methylation in B-cell chronic lymphocytic leukemia (CLL). Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2555-2560.	3.3	58
16	<i>MicroRNA</i> dysregulation to identify therapeutic target combinations for chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 10731-10736.	3.3	48
17	Identification of tRNA-derived small RNA (tsRNA) responsive to the tumor suppressor, RUNX1, in breast cancer. Journal of Cellular Physiology, 2020, 235, 5318-5327.	2.0	48
18	MIR-181b: new perspective to evaluate disease progression in chronic lymphocytic leukemia. Oncotarget, 2012, 3, 195-202.	0.8	46

#	ARTICLE	IF	CITATIONS
19	Dysregulation of different classes of tRNA fragments in chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 24252-24258.	3.3	45
20	Identification of tRNA-derived ncRNAs in TCGA and NCI-60 panel cell lines and development of the public database tRFexplorer. Database: the Journal of Biological Databases and Curation, 2019, 2019, .	1.4	36
21	A Sleeping Beauty screen reveals NF- $\kappa$ B activation in CLL mouse model. Blood, 2013, 121, 4355-4358.	0.6	31
22	Novel Mechanisms of Regulation of miRNAs in CLL. Trends in Cancer, 2016, 2, 134-143.	3.8	30
23	miR Deregulation in CLL. Advances in Experimental Medicine and Biology, 2013, 792, 309-325.	0.8	23
24	MicroRNA dysregulation and multi-targeted therapy for cancer treatment. Advances in Biological Regulation, 2020, 75, 100669.	1.4	20
25	Novel Insights in Molecular Mechanisms of CLL. Current Pharmaceutical Design, 2012, 18, 3363-3372.	0.9	14
26	Role of Non-Coding RNAs in the Development of Targeted Therapy and Immunotherapy Approaches for Chronic Lymphocytic Leukemia. Journal of Clinical Medicine, 2020, 9, 593.	1.0	13
27	MicroRNA Profiling of Salivary Duct Carcinoma Versus Her2/Neu Overexpressing Breast Carcinoma Identify miR-10a as a Putative Breast Related Oncogene. Head and Neck Pathology, 2019, 13, 344-354.	1.3	12
28	Translocation t(2;11) in CLL cells results in CXCR4/MAML2 fusion oncogene. Blood, 2014, 124, 259-262.	0.6	11
29	HNRNP1 Restrains miR-155 Targeting of BUB1 to Stabilize Aberrant Karyotypes of Transformed Cells in Chronic Lymphocytic Leukemia. Cancers, 2019, 11, 575.	1.7	11
30	Small Non-Coding RNAs in Leukemia. Cancers, 2022, 14, 509.	1.7	7
31	Genetic dynamics in untreated CLL patients with either stable or progressive disease: a longitudinal study. Journal of Hematology and Oncology, 2019, 12, 114.	6.9	5
32	A large fraction of trisomy 12, 17p <sup>+</sup> , and 11q <sup>+</sup> CLL cases carry unidentified microdeletions of <i>miR-15a/16-1</i> . Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	3
33	In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation. Journal of Cell Biology, 2013, 201, 14-14.	2.3	0